Literature DB >> 11029409

Enhanced Na(+) channel intermediate inactivation in Brugada syndrome.

D W Wang1, N Makita, A Kitabatake, J R Balser, A L George.   

Abstract

Brugada syndrome is an inherited cardiac disease that causes sudden death related to idiopathic ventricular fibrillation in a structurally normal heart. The disease is characterized by ST-segment elevation in the right precordial ECG leads and is frequently accompanied by an apparent right bundle-branch block. The biophysical properties of the SCN5A mutation T1620M associated with Brugada syndrome were examined for defects in intermediate inactivation (I:(M)), a gating process in Na(+) channels with kinetic features intermediate between fast and slow inactivation. Cultured mammalian cells expressing T1620M Na(+) channels in the presence of the human beta(1) subunit exhibit enhanced intermediate inactivation at both 22 degrees C and 32 degrees C compared with wild-type recombinant human heart Na(+) channels (WT-hH1). Our findings support the hypothesis that Brugada syndrome is caused, in part, by functionally reduced Na(+) current in the myocardium due to an increased proportion of Na(+) channels that enter the I:(M) state. This phenomenon may contribute significantly to arrhythmogenesis in patients with Brugada syndrome. The full text of this article is available at http://www.circresaha.org.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11029409     DOI: 10.1161/01.res.87.8.e37

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  45 in total

1.  Na(+) channel mutation that causes both Brugada and long-QT syndrome phenotypes: a simulation study of mechanism.

Authors:  Colleen E Clancy; Yoram Rudy
Journal:  Circulation       Date:  2002-03-12       Impact factor: 29.690

Review 2.  Defective cardiac ion channels: from mutations to clinical syndromes.

Authors:  Colleen E Clancy; Robert S Kass
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

3.  Quantitative modelling of interaction of propafenone with sodium channels in cardiac cells.

Authors:  M Pásek; J Simurda
Journal:  Med Biol Eng Comput       Date:  2004-03       Impact factor: 2.602

4.  A computational model of the human left-ventricular epicardial myocyte.

Authors:  Vivek Iyer; Reza Mazhari; Raimond L Winslow
Journal:  Biophys J       Date:  2004-09       Impact factor: 4.033

5.  Mechanistic links between Na+ channel (SCN5A) mutations and impaired cardiac pacemaking in sick sinus syndrome.

Authors:  Timothy D Butters; Oleg V Aslanidi; Shin Inada; Mark R Boyett; Jules C Hancox; Ming Lei; Henggui Zhang
Journal:  Circ Res       Date:  2010-05-06       Impact factor: 17.367

Review 6.  Inherited disorders of voltage-gated sodium channels.

Authors:  Alfred L George
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

Review 7.  Computational biology in the study of cardiac ion channels and cell electrophysiology.

Authors:  Yoram Rudy; Jonathan R Silva
Journal:  Q Rev Biophys       Date:  2006-07-19       Impact factor: 5.318

8.  A sodium channel pore mutation causing Brugada syndrome.

Authors:  Arnold E Pfahnl; Prakash C Viswanathan; Raul Weiss; Lijuan L Shang; Shamarendra Sanyal; Vladimir Shusterman; Cari Kornblit; Barry London; Samuel C Dudley
Journal:  Heart Rhythm       Date:  2006-09-28       Impact factor: 6.343

Review 9.  Brugada syndrome: current clinical aspects and risk stratification.

Authors:  Takanori Ikeda
Journal:  Ann Noninvasive Electrocardiol       Date:  2002-07       Impact factor: 1.468

10.  The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome.

Authors:  Naomasa Makita; Elijah Behr; Wataru Shimizu; Minoru Horie; Akihiko Sunami; Lia Crotti; Eric Schulze-Bahr; Shigetomo Fukuhara; Naoki Mochizuki; Takeru Makiyama; Hideki Itoh; Michael Christiansen; Pascal McKeown; Koji Miyamoto; Shiro Kamakura; Hiroyuki Tsutsui; Peter J Schwartz; Alfred L George; Dan M Roden
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.